Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for First Dual-Functional RNAi Therapeutics for Mixed Hyperlipidemia

On September 15, 2026, Arrowhead Pharmaceuticals shared early results from a Phase 1/2a study of ARO-DIMER-PA, an experimental RNAi therapy that targets PCSK9 and APOC3 with one molecule. This initiative lowered LDL cholesterol, non-HDL cholesterol, triglycerides, and ApoB.

The treatment led to strong reductions in both targets, with average maximum drops of 72% for PCSK9 and 88% for APOC3. These results mark a major step for Arrowhead’s dual-action RNAi approach and may help advance therapies that challenge numerous lipid problems linked to heart disease with a single treatment.

Impact on the Biotechnology Industry

The global biotechnology market size is estimated at USD 1.77 trillion in 2025 and predicted to increase from USD 2.02 trillion in 2026 to approximately USD 6.34 trillion by 2035, representing a CAGR of 13.61% from 2026 to 2035.

According to Precedence Research, there is interest in the biotechnology sector in RNAi platforms that are able to target several biological pathways using one therapy. Arrowhead's method demonstrates that RNAi technology can move towards the simple suppression of a single gene and support more complicated treatment strategies.

The development may encourage pharmaceutical companies to consider multi-target RNAi drugs and the substantial investment in oligonucleotide technologies. It will result in greater competition in research into cardiovascular and metabolic diseases, especially in sectors where existing treatments do not completely deal with cardiovascular risk.

Impact on the Cardiovascular Drugs Industry

The global cardiovascular drugs market size is calculated at USD 155.96 billion in 2025 and is predicted to increase from USD 162.02 billion in 2026 to approximately USD 221.20 billion by 2035, expanding at a CAGR of 3.56% from 2026 to 2035.

According to Precedence Research, cardiologist focuses to verify these initial findings and demonstrate actual clinical benefits. This could lead to new methods of treating mixed hyperlipidemia, a condition characterised by various kinds of abnormal lipid levels, not merely by having high LDL cholesterol.
 A treatment that has an effect on both PCSK9 and APOC3 at the same time might provide a greater lipid-lowering effect with a single therapy. This method could be used in conjunction with well-established cardiovascular treatments and give doctors an additional choice when it comes to patients with difficult-to-manage lipid risks.

Impact on the Drug Discovery Industry

The global drug discovery market size was valued at USD 71.89 billion in 2025 and is predicted to increase from USD 78.51 billion in 2026 to approximately USD 171.36 billion by 2035, expanding at a CAGR of 9.07% from 2026 to 2035.

According to Precedence Research, the pharmaceutical sector is transforming towards a modern blend and influencing future drug-development strategies. Arrowhead’s clinical validation of a dual-functional RNAi molecule could represent a meaningful development for the broader RNA therapeutics field. 
Successfully silencing two genes with one molecule may expand how researchers think about RNA-based medicines and create opportunities for multi-target approaches in other complex diseases. The growing move towards gene silencing, particularly for conditions driven by interconnected biological pathways that may be difficult to address through conventional single-target medicines.

Expert Opinion

From an expert perspective, these early results are crucial because they show that one RNAi molecule can strongly suppress two key genes and improve several lipid measures. This idea is especially promising for mixed hyperlipidemia, where lowering only LDL cholesterol may not be enough to reduce cardiovascular risk.

Experts observed that these are early findings, and larger studies are required to confirm how long the effects last to assess treatment safety, the right dosing, and whether these changes lead to improved heart health. If future studies support these results, ARO-DIMER-PA could become a key example of multi-target RNAi technology.